We report a successful case of living-donor lobar lung transplantation (LDLLT) for therapy-resistant broncho-bronchiolitis obliterans (BBO) after allogeneic hematopoietic stem cell transplantation (HSCT). Bronchiolitis obliterans (BO) is one of the late-onset noninfectious pulmonary complications that occur after allogeneic HSCT and is usually resistant to immunosuppressive therapy. A 17-year-old girl with acute lymphoblastic leukemia (ALL) had undergone allogeneic bone marrow transplantation (BMT) from an HLA-matched sibling in 1997. Five years later, she relapsed with ALL and was treated with chemotherapy following stem cell rescue and donor lymphocyte infusion from the original BMT donor. Eight months later, BBO resistant to immunosuppressive therapies, including rituximab, developed in combination with chronic graft-versus-host disease (GVHD). In February 2004, the patient underwent LDLLT from 2 other family members who were mismatched at 3 HLA loci. The patient has been in good health for more than 30 months following LDLLT and shows no sign of BBO in the transplanted lungs, just as with other patients who have undergone lung transplantation for BO associated with chronic GVHD. LDLLT may therefore be considered a viable therapeutic option for the treatment of BO after allogeneic HSCT.
Introduction
Pulmonary complications develop in 40% to 60% of recipients of allogeneic hematopoietic stem cell transplantation (HSCT) [1] [2] [3] . In 1998, Palmas et al [4] defined noninfectious pulmonary complications that occur later than 3 months after allogeneic SCT as late-onset noninfectious pulmonary complications (LONIPCs). Once LONIPCs occur, the recipient's quality of life is markedly impaired; therefore, LONIPCs are recognized as a major cause of morbidity and mortality after allogeneic HSCT [4, 5] . LONIPCs include bronchiolitis obliterans (BO), bronchiolitis obliterans with organizing pneumonia (BOOP), diffuse alveolar damage, lymphocytic interstitial pneumonia (LIP), and nonclassifiable interstitial pneumonia (NCIP) [4] . Although the pathogenesis of LONIPCs remains unclear, LONIPCs are strongly associated with chronic graft-versus-host disease (GVHD) [4, 6, 7] . Immunosuppressive therapies have been considered to be the standard treatments for LONIPCs. In fact, LIP, NCIP, and BOOP have all been shown to successfully respond to these treatments [4, 7] . BO, however, is usually resistant to such treatments [4, 7, 8] . The mortality rate for BO following allogeneic HSCT therefore may be as high as 100% [1, 9, 10] .
Lung transplantation (LT) is an alternative therapeutic option for BO in some selected patients; however, the longterm efficacy of LT for BO and the recurrence rate of BO in transplanted lungs are unknown. We describe a patient who underwent living-donor lobar LT (LDLLT) for therapyresistant BO after allogeneic HSCT and who has demonstrated no disease recurrence for more than 30 months after LDLLT.
Case Report
A 17-year-old girl received a diagnosis of acute lymphoblastic leukemia (ALL) in February 1997. She was treated with combination chemotherapy [11] and obtained complete remission. The patient underwent allogeneic bone marrow transplantation from her HLA-matched sibling in July 1997. The preconditioning regimen consisted of 3 Gy total body irradiation once daily for 4 consecutive days (total dose, 12 Gy), 2 g/m 2 cytarabine administered intravenously twice daily for 2 consecutive days (total, 4 doses), and 60 mg/kg cyclophosphamide administered intravenously once daily for 2 consecutive days (total dose, 120 mg/kg). GVHD prophylaxis consisted of cyclosporine (CsA) and short-term methotrexate. No GVHD was observed, and CsA was tapered off until February 1998. The patient relapsed with ALL in October 2002. An anthracycline-containing regimen [11] induced a second complete remission. Eight days after consolidation therapy consisting of 2 g/m 2 cytarabine administered intravenously twice daily for 5 consecutive days (total, 10 doses), the patient received donor buffy coat containing 5. Figure 1) . A bronchofiberscopy examination showed obstructions at the level of the broncho-bronchiols, predominantly in the lower lobes on both sides. The patient then received a diagnosis of broncho-bronchiolitis obliterans (BBO), a variant of BO. The CsA dose was increased, and oral administration of prednisolone was initiated; however, no response was observed. As the patient's symptoms worsened, CsA was replaced with tacrolimus. In addition, rituximab was administered at 375 mg/m 2 once a week for 4 weeks to treat scleroderma caused by the chronic GVHD [12] . We concluded that scleroderma had partially contributed to her constrictive respiratory failure by limiting chest wall compliance; however, the patient's respiratory failure associated with hypercapnia became exacerbated to such a degree that she became completely dependent on oxygen support. The patient became totally bedridden and had to undergo a tracheostomy in January 2004 to receive mechanical ventilation. At this time, her family requested that LT be performed. The patient was considered a candidate for LDLLT because she had end-stage BO (which is listed as a clinical status meeting the indication criteria for LT), because of the impossibility of waiting for a cadaveric lung graft owing to her rapid exacerbation of respiratory failure, and because there were no contraindications for LT except for the coexistence of malignant disease [13, 14] . The patient's ALL had been in the second complete remission for more than a year, however, and the level of Wilms tumor gene in the bone marrow was 120 copies/μg RNA, thus indicating a low potential for an ALL relapse [15] . The ethics committee of the lung-transplantation center approved LDLLT for this patient because she was considered to have neither newly treated malignant disease nor widespread malignancy. LDLLT was performed on February 16, 2004 , with a right lower lobe from her older brother (who was mismatched at 3 HLA loci in the direction of graft rejection) and a left lower lobe from her mother, who was mismatched at 3 antigens in the direction of graft rejection ( Table 1) . The patient's own lungs were removed completely. The ABO antigens of the recipient and donors were compatible ( Table 1 ). The immunosuppressive therapy to prevent graft rejection consisted of tacrolimus, prednisolone, and azathioprine. Signs of acute rejection appeared after LDLLT, but rejection was successfully avoided by the intravenous administration of methylprednisolone and mycophenolate mofetil. The hypercapnia rapidly improved, and the vital capacity increased immediately after LDLLT. This progress allowed the patient to be weaned from mechanical ventilation on day 15, and she was discharged from the hospital on day 64 after LDLLT. BBO has not recurred in the transplanted lungs, and tests of pulmonary function have shown improvements in both the FVC and FEV1.0 for more than 30 months following LDLLT, despite the persistence of dry eyes and impaired lacrimal secretion. A pathologic examination of the explanted lungs revealed focal desquamation of the broncho-bronchiolar epithelium with an aggregate of foamy macrophages and lymphocytes and occlusions of the broncho-bronchiolar lumen, observations compatible with a diagnosis of either BBO or BO [16] .
Discussion
BO is one of the LONIPCs and occurs 3 to 15 months following allogeneic HSCT [4, 5, 7, 8] . The clinical symptoms of BO include a nonproductive cough, rapidly progressive dyspnea, and wheezing. The incidence of BO following allogeneic HSCT varies from 2.7% to 7.6% according to the published studies [4, 7, 8] . BO is one of the most devastating complications of allogeneic HSCT. Once it occurs in a patient, the prognosis tends to be extremely poor. The mortality rate reportedly varies from 14% to 100% [7, 17, 18] . The response to BO treatment has a significant effect on survival: 79% of responders survived more than 5 years from the diagnosis of BO, but only 13% of nonresponders survived [8] . Patients with LONIPCs have been treated with immunosuppressive agents such as antithymocyte globulin, methylprednisolone, prednisolone, CsA, tacrolimus, and azathioprine. Most patients with LIP and BOOP responded well to such treatments, whereas only 16% to 49% of BO patients improved owing to these treatments [4, 7, 8] . Consequently, no standard therapy for BO has yet been established.
Because BO often develops in association with chronic GVHD, this complication is thought to be one of the pulmonary manifestations of chronic GVHD [7, 8, 19] . However, the development of BO following autologous bone marrow transplantation in 2 patients [20] and a lower incidence of BO in recipients of allogeneic HSCT following reduced-intensity conditioning than in HSCT recipients with myeloablative conditioning [21] suggest that tissue damage due to high-dose radiochemotherapy plays a role in the development of BO. Our patient had extensive chronic GVHD, as manifested by sicca symptoms, at the time of LDLLT, and these symptoms persisted for more than 30 months, even after LDLLT. Because her lungs were suspected to be a target of the chronic GVHD, an LT from the donor of the allogeneic HSCT was thought to be ideal; however, because the donor and patient's family did not consent, she received an LT from 2 family members who were mismatched at 3 HLA loci. Despite the presence of HLA mismatches between the lung donors and the patient and the persistence of chronic GVHD, there has been no recurrence of BO in the transplanted lungs.
Fifteen cases of LT for post-SCT pulmonary complications following allogeneic HSCT, including 10 BO patients, have been reported (Table 2) [22] [23] [24] [25] [26] [27] [28] [29] . The indications for LT in patients demonstrating BO following allogeneic HSCT are limited by many factors, such as the criteria of the donor and recipient, the existence of a suitable donor, the status of hematologic disease, and the timing of LT, especially for LDLLT [30] . Four of the 10 BO patients died after LT [24, 27, 29] . The patient in case 7 died of chronic rejection 6 years after undergoing LT, patient 11 died of pulmonary hemorrhaging 3 weeks after receiving LT, and patient 3, who received a single LT from a cadaver, died of BO on day 271, following recurrent episodes of both perivascular and bronchial rejection. Pechet et al [29] described 2 patients who had complications of BO long after LT; however, the authors did not report the details of these patients. The development of post-LT BO was thought to be due in part to a manifestation of chronic rejection [31, 32] ; however, preexisting chronic GVHD may have played some role in the development of BO in the transplanted lung early after transplantation. The other 5 BO patients (except for those described by Pechet et al [29] ) and our patient have not experienced BO in the transplanted lungs from more than 15 months to 6 years after LT, despite the existence of chronic GVHD. These findings indicate that factors other than chronic GVHD, such as highdose chemoradiotherapy and viral infections, may contribute to the development of BO following allogeneic HSCT. Another possibility is that the development of BO may require the presence of specific minor histocompatibility antigen (mHa) mismatches between the donor of the LT and the patient's immune system. The transplanted lungs may have evaded the immune attack responsible for BO because of a lack of mHas mismatches. LT is therefore considered to be a promising therapy for BO, even for patients associated with active chronic GVHD.
